Cardarine (GW-501516)

You’ll often see Cardarine (GW-501516) sold and talked about right next to SARMs in the “research chemical” market. But it’s actually a completely different kind of substance. It’s a synthetic PPARδ agonist — not a peptide, and not a SARM. It got early attention as an “exercise mimetic” (a drug meant to copy some of the effects of working out) because switching on PPARδ in muscle ramps up how the body burns fat for fuel. The catch: its development was dropped after long-term animal studies turned up cancer in several organs, and no human trial has ever tested it for athletic performance, fat loss, or long-term safety.

What it is

GW-501516 (also called GW1516, Endurobol, or Cardarine) is a small, synthetic molecule that switches on PPARδ (peroxisome proliferator-activated receptor delta — a protein that helps control how cells use fat and energy). It is not a peptide and not a SARM. SARMs work by acting on the androgen receptor (the body’s testosterone-sensing switch), and GW-501516 does not do that. Because it usually gets lumped in with SARMs in the unregulated research-chemical market, a lot of people misunderstand what it actually is. When PPARδ gets switched on in muscle, the muscle turns up genes that govern fat-burning and energy production — and that’s where the “exercise in a pill” idea comes from. It was originally developed as a possible treatment for dyslipidemia (unhealthy blood-fat levels) and metabolic disease, and it was never approved for any use.

The claims

Sellers and users say Cardarine boosts endurance (“exercise in a pill”), burns fat, improves running and stamina, and shifts blood fats in a good direction — for example, raising HDL (“good” cholesterol) and lowering triglycerides (a type of fat in the blood). It’s sold online as a “research chemical,” or sometimes falsely passed off as a supplement ingredient.

What the evidence actually shows

The human data we have is limited to a few short trials looking at metabolism. There are no human trials for athletic performance, fat loss, or long-term safety.

• Healthy-volunteer trial (Sprecher et al., 2007): This was the first time a PPARδ agonist was reported in humans. Healthy, inactive men took either a placebo or GW-501516 for two weeks. Triglycerides trended downward, and the body cleared fat from the blood a bit faster after a fatty meal. But the group was small, the study was short, and the men were sedentary (not physically active).
• Low-HDL patient trial (Olson, Pearce, Jones, Sprecher, 2012): This was a randomized, placebo-controlled trial (n=268) in people with low HDL. At the highest dose, GW-501516 raised HDL-C by up to 16.9% and lowered triglycerides (-16.9%), LDL (“bad” cholesterol, ~-7.3%), apoB (a protein on LDL particles, ~-14.9%), and free fatty acids. This is the largest pool of human data we have — but it was still short, and it only measured blood-fat numbers. It tells us nothing about real heart outcomes like heart attacks.
• Animal endurance evidence: The famous “exercise mimetic” result — where switching on PPARδ plus training boosted running endurance — comes from mouse studies (Narkar et al., Cell 2008). It has not been repeated in humans.

So there’s a reasonable biological story and some endurance data in rodents, but the supposed performance and fat-loss benefits in people remain unproven. Development was stopped before anyone could establish whether it actually works in humans.

Legal and regulatory status

United States (FDA): GW-501516 has no approved use. SARMs and SARM-like research chemicals sold as supplements are not legal dietary-supplement ingredients — the FDA’s stance is that they are unapproved drugs that don’t comply with DSHEA (the law that governs dietary supplements). The FDA sent out warning letters in 2017 and issued a consumer warning flagging risks for the broader SARM category, including liver damage, heart attack, and stroke.

DEA scheduling: GW-501516 is not a federally scheduled controlled substance in the US. A “SARMs Control Act” has been proposed in past sessions of Congress to schedule certain SARMs, but GW-501516 is not DEA-scheduled — and since it’s a PPARδ agonist rather than a SARM, it wouldn’t necessarily be covered by such an act anyway. (For comparison: oxandrolone is a separate, FDA-approved anabolic-androgenic steroid and a Schedule III controlled substance under the Anabolic Steroid Control Act. It’s unrelated to GW-501516.)

Australia: GW-501516 is classified as a poison/prohibited substance.

Anti-doping (WADA): GW-501516 (GW1516) is banned at all times — both in and out of competition — under Section S4.5 “Metabolic Modulators” (part of S4, Hormone and Metabolic Modulators), which covers PPARδ agonists and the PPARδ-AMPK axis (a related energy-sensing pathway). WADA added it to the Prohibited List in 2009 once they had a test to detect it. SARMs (ostarine, andarine, LGD-4033, RAD140, and others) are banned under a different category, S1.2 “Other Anabolic Agents.” USADA has reported 31 sanctions worldwide for GW-501516 detection in 2017 alone.

Safety

Cancer is the big concern. GSK/Ligand stopped development around 2007 because long-term rodent carcinogenicity studies (animal studies that test whether a substance causes cancer) found tumors in multiple organs — a result confirmed by USADA and Sport Integrity Australia. The full two-year mouse cancer study is most accurately described as toxicology work presented in conference/abstract form rather than a fully peer-reviewed article, but the cancer finding itself is well backed up by several independent anti-doping and review sources. This is the single most important safety signal: a known multi-organ cancer finding at the kinds of doses and durations that long-term use would require. WADA and USADA have issued formal safety alerts warning athletes and consumers off GW-501516 specifically because of this cancer risk.

Hormonal effects: GW-501516 is a metabolic modulator, not a hormone, and it is not established to cause testosterone suppression the way SARMs and anabolics do. Lowered testosterone, reduced HDL, and liver toxicity are documented worries for SARMs (a different class) — those harms shouldn’t be pinned on GW-501516.

A note on vision claims: The yellow-tinted vision and trouble seeing at night that people report online actually belong to andarine (S-4), a SARM, and come from the way it acts on tissue in the eye (the retina). That’s a property of andarine, not GW-501516, and it’s mentioned here only to draw the contrast.

Quality risk: Products sold as “Cardarine” are unregulated, and lab analyses have found mislabeling, the wrong compounds, and contamination.

There is no verifiable published finding of QT prolongation (a heart-rhythm change) or blindness attributable to GW-501516 itself, so those claims are left out here rather than repeated.

Bottom line

Cardarine (GW-501516) has some early human data showing it can shift blood fats in a favorable direction over the short term, plus rodent data hinting at endurance benefits — but there’s no human evidence for performance, fat loss, or long-term safety. Most important of all: its development was abandoned because long-term animal studies found cancer in multiple organs. It has no approved human use, is sold only as an unregulated research chemical, and is banned in sport at all times. That proven cancer signal in animals is the decisive reason for caution.

Evidence grade: 7/10 · Moderate.

Sources

• GW501516 — Wikipedia
• Sprecher DL et al. (2007), Arterioscler Thromb Vasc Biol — PMID 17110604
• Olson EJ, Pearce GL, Jones NP, Sprecher DL (2012), Arterioscler Thromb Vasc Biol — PMID 22814748
• Narkar VA et al. (2008), Cell — PMID 18674809
• USADA — What Should Athletes Know About GW1516?
• Sport Integrity Australia — GW1516 information
• WADA Prohibited List
• FDA — Certain Bodybuilding Products … SARMs Cause Harm
• FDA — Consumer update on SARMs among teens and young adults